Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) — shareholding pattern, promoter holding, financials and share price
About Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS)
Aarey Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AAREYDRUGS and on the BSE under scrip code 524412. Its ISIN is INE198H01019.
Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse industrial applications [1]
Aarey Drugs & Pharmaceuticals Ltd, founded in 1990, manufactures and supplies pharmaceutical raw materials, chemicals, and API drugs.
The company underwent a significant transition in 1993 when the Aarey Group took over and rebranded the company from Niharika Textiles & Chemicals.
Listed peers in Pharmaceuticals: Lyka Labs Ltd, Gennex Laboratories Ltd, Ambalal Sarabhai Enterprises Ltd, Nectar Lifescience Ltd, Kerala Ayurveda Ltd, Coral Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹85.46 a share on 10 Jul 2026, Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) was valued at a price-to-earnings ratio of 53.61x against an industry P/E of 36.41x and a price-to-book of 1.75x on a book value of ₹48.84 per share as of Mar 2025. Solomo computes return on equity of 3.26% and return on capital employed of 6.01% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 53.61x
- Industry P/E
- 36.41x
- P/B
- 1.75x
- EPS (TTM)
- ₹1.59
- Book value / share
- ₹48.84
- ROE
- 3.26%
- ROCE
- 6.01%
- ROA
- 1.56%
- Debt / equity
- 0.25x
- Dividend yield
- 0%
- EBITDA margin
- 2.81%
- 52-week range
- ₹50.4 – ₹100
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) reported revenue of ₹472 crore, net profit of ₹4 crore and earnings per share of ₹1.4. That compares with revenue of ₹474 crore and net profit of ₹4 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹189.47 crore and net profit ₹1.56 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 493 | 419 | 396 | 474 | 472 |
| Net profit (₹ cr) | 7 | 4 | 5 | 4 | 4 |
| EPS (₹) | 2.58 | 1.49 | 1.67 | 1.42 | 1.4 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 7.56% | 9.57% | -1.29% | 19.80% |
| Profit growth | 13.48% | -7.03% | -15.01% | -14.10% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 37.71% of Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) (unchanged from the previous quarter), foreign institutional investors (FII) hold 4.8% and domestic institutional investors (DII) hold 1.62%. Market capitalisation was ₹242 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Elysian Wealth Fund 3.12%, HUF 1.85%, Krishnamurthy C G 1.76%, Suvi Rubber Pvt Ltd 1.65%, Shree Salasar Properties And Finance Private Limited 1.62%, Chetan Kirtibhai Mehta 1.41%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 37.71% | - | 4.8% | 1.62% | 62.29% |
| Mar 2026 | 37.71% | - | 4.18% | 1.62% | 62.29% |
| Dec 2025 | 39.06% | - | 3.86% | - | 60.94% |
| Sep 2025 | 44.8% | - | 1.13% | - | 55.2% |
| Jun 2025 | 44.8% | - | 1.97% | - | 55.2% |
| Mar 2025 | 44.8% | - | 2.34% | - | 55.2% |
| Dec 2024 | 44.8% | - | 2.34% | - | 55.2% |
| Sep 2024 | 45.44% | - | 2.75% | - | 54.56% |